Volume 8.10 | Mar 17

Mammary Cell News 8.10 March 17, 2016
Mammary Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  MCN on Twitter
First Injectable Nanoparticle Generator Could Radically Transform Metastatic Breast Cancer Treatment
A team of investigators may have transformed the treatment of metastatic triple negative breast cancer by creating the first drug to successfully eliminate lung metastases in mice. [Press release from Houston Methodist Research Institute discussing online prepublication in Nature Biotechnology] Press Release | Abstract
Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells
PUBLICATIONS (Ranked by impact factor of the journal)

A Preclinical Model for ERα-Positive Breast Cancer Points to the Epithelial Microenvironment as Determinant of Luminal Phenotype and Hormone Response
The authors showed that the traditional grafting of estrogen receptor α positive (ER+) tumor cells into mammary fat pads induces TGFβ/SLUG signaling and basal differentiation when they require low SLUG levels to grow in vivo. [Cancer Cell] Abstract | Graphical Abstract

Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Using transgenic mouse models, cell line-based functional studies, and clinical specimens, researchers showed that cyclin D1/CDK4 mediate resistance to targeted therapy for HER2-positive breast cancer. [Cancer Cell] Abstract | Press Release

Loss of miR-203 Regulates Cell Shape and Matrix Adhesion through ROBO1/Rac/FAK in Response to Stiffness
Investigators observed that Robo1 ablation in the developing mammary gland compromised actin stress fiber assembly and inhibited cell contractility to perturb tissue morphogenesis, whereas SLIT2 treatment stimulated Rac and increased focal adhesion kinase activity to enhance cell tension by maintaining cell shape and matrix adhesion. [J Cell Biol] Abstract | Editorial | Press Release

Cyclophilin D Counteracts P53-Mediated Growth Arrest and Promotes Ras Tumorigenesis
Using cellular and in vivo mouse models, the authors demonstrated that cyclophilin D protein upregulation induced by oncogenic Ras through the Raf-1/MEK/ERK pathway has a deterministic role in tumor progression. [Oncogene] Abstract

Zoledronic Acid-Encapsulating Self-Assembling Nanoparticles and Doxorubicin: A Combinatorial Approach to Overcome Simultaneously Chemoresistance and Immunoresistance in Breast Tumors
Nanoparticle-based zoledronic acid-containing formulation reduced the IC50 of doxorubicin in human and murine chemoresistant breast cancer cells and restored the doxorubicin efficacy against chemo-immunoresistant tumors implanted in immunocompetent mice. [Oncotarget] Full Article

Suppression of Spry1 Inhibits Triple-Negative Breast Cancer Malignancy by Decreasing EGF/EGFR Mediated Mesenchymal Phenotype
Scientists reported that sprouty 1 (Spry1) is significantly expressed in triple-negative breast cancer (TNBC) specimen and MDA-MB-231 cells. To understand Spry1 regulation of signaling events controlling breast cancer phenotype, they used lentiviral delivery of human Spry1 shRNAs to suppress Spry1 expression in MDA-MB-231, an established TNBC cell line. [Sci Rep] Full Article


Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib plus Anastrozole Compared with Anastrozole Alone in Patients with Estrogen Receptor-Positive Breast Cancer
Postmenopausal women with newly diagnosed operable estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancers were recruited. Participants were randomly allocated to two weeks of preoperative treatment with anastrozole 1 mg once per day or the combination of anastrozole 1 mg with pictilisib 260 mg once per day. [J Clin Oncol] Abstract

Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and Doxorubicin Pharmacokinetics in Asian Breast Cancer Patients
Researchers investigated the impact of ABCB5, ABCC5 and RLIP76 polymorphisms on doxorubicin pharmacokinetics in Asian breast cancer patients. [Pharmacogenomics J] Abstract

Learn More: Standardized Tools for Cancer Research
Developmental Signaling Pathways Regulating Mammary Stem Cells and Contributing to the Etiology of Triple-Negative Breast Cancer
The authors present evidence of the involvement of Cripto-1, Notch/CSL, and Wnt/β-catenin in the normal mammary gland morphogenesis and tumorigenesis, from fetal mammary stem cell/adult mammary stem cell regulation to tumor-initiating cell generation and maintenance in triple-negative breast cancer. [Breast Cancer Res Treat] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Combination of Lapatinib and Trastuzumab Shrinks HER2 Positive Breast Cancer Significantly in 11 Days after Diagnosis
Approximately a quarter of women with HER2 positive breast cancer, who were treated with a combination of the targeted drugs lapatinib and trastuzumab before surgery and chemotherapy, saw their tumors shrink significantly or even disappear, according to results from a clinical trial. [Press release from The University of Manchester discussing research presented at 10th European Breast Cancer Conference (EBCC-10), Amsterdam] Press Release

Genomic Health Announces Five-Year Outcomes from International ‘PlanB’ Study Demonstrating the Clinical Utility of Oncotype DX® in Node-Positive and High-Risk Node-Negative Breast Cancer
Genomic Health, Inc. announced new five-year clinical outcomes results from a large PlanB study, which was highlighted as an oral presentation. The study, conducted by the West German Study Group (WSG), showed that 94 percent of early-stage breast cancer patients with Oncotype DX® Recurrence Score® results of 11 or less, who were treated with hormonal therapy alone, were disease-free five years after diagnosis. [Press release from Genomic Health, Inc. discussing research to be presented at the 10th European Breast Cancer Conference (EBCC-10), Amsterdam] Press Release

From our sponsor: Working with blood? Request your free wallchart on human blood cell frequencies.
Allergan Confirms Generic Abraxane® Patent Challenge
Allergan plc confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market paclitaxel protein-bound particles for injectable suspension. Allergan’s ANDA product is a generic version of Celgene’s Abraxane®, which is indicated for the treatment of metastatic breast cancer. [Allergan plc (PR Newswire Association LLC)] Press Release

SRI International Receives $19.8 Million National Cancer Institute Contract for PREVENT Cancer Program
SRI International has been awarded a contract of up to $19.8 million from the National Cancer Institute PREVENT Cancer Preclinical Drug Development Program to support the development of potential cancer preventive agents or vaccines. [SRI International] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Cell Signaling in Cancer: From Mechanisms to Therapy
June 5-10, 2016
Snowmass Village, United States

Visit our events page to see a complete list of events in the mammary cell community.
NEW PhD Fellowship – Breast Cancer (INCLIVA Health Research Institute)

NEW Postdoctoral Fellowship – Platelets in Metastatic Breast and Colon Cancer (Université de Strasbourg)

Research Associate – Breast Cancer and Huntington’s Disease (University of Pittsburgh Drug Discovery Institute)

Research Associate – Vascular Biology and Breast Cancer (University of South Australia)

Postdoctoral Fellowship – Tumor Biology of Breast and Lung Cancer (Cold Spring Harbor Laboratory)

Research Technician – Breast Cancer (Kings College London)

Research Associate – Breast Cancer (University of Cambridge)

Postdoctoral Fellowship – Breast Cancer Stem Cells (Fundación para la Investigación Biosanitaria de Andalucia Oriental)

Postdoctoral Fellowship – Microenvironment of Breast Cancer (Icahn School of Medicine)

Postdoctoral Fellowship – Breast and Prostate Cancer Molecular Mechanisms (Feinberg School of Medicine)

Postdoctoral Fellowship – Epigenetic Reprogramming of Breast Cancer Stem Cells (University of Toronto)

Postdoctoral Fellowship – Various Projects in Cancer Biology (National University of Singapore)

Postdoctoral Fellowship – Genetic and Epigenetic Variability in Breast Cancer (The University of Tennessee Health Science Center)

Pathologist – Breast/Gastrointestinal/Genitourinary Cancer (Beth Israel Deaconess Medical Center)

Manager – Medical and Breast Imaging (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellowship – Breast Cancer Biology (Washington University School of Medicine)

Clinical Pathways Associate – Cancer Therapeutics (Fred Hutchinson Cancer Research Center)

Director Clinical Research – Medical Oncology (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us